A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin
Lispro.
The aim of this trial is to assess the efficacy and safety of BioChaperone® Combo in subjects
with type 1 diabetes under a dose of 0.8 U/kg.
This trial is a phase 1 single-center, randomized, double-blinded, two-treatment, two-period
cross-over, 30-hour euglycaemic glucose clamp trial in subjects with type 1 diabetes
mellitus. Each subject will be randomly allocated to one single dose of 0.8 U/kg of
BioChaperone® Combo and to one single dose of 0.8 U/kg of Humalog® Mix 25 on two separate
dosing visits.